


Amanda Jan¹, Nicolson Modesti², Isabella Barcellos², David Isaacs², Sarah Woidill², Ani Dixit², Russell D'Aiello², Zaida Flores², Francesco Gavazzi², Kayla Muirhead², Bridget Slattery², Omar Sherbini², Justine Shults³, Ariel Vincent², Adeline Vanderver², Laura Adang²

¹ School of Medicine, University of California Davis, Sacramento, CA, USA
² Division of Neurology, Children's Hospital of Philadelphia, Philadelphia, PA, USA
³ Department of Statistics, University of Pennsylvania, Philadelphia, PA, USA

Background

Aicardi Goutières Syndrome (AGS) is a heritable interferonopathy that results in variable neurologic disability and systemic complications¹. Key variables (e.g. genotype and age at onset) only partially correlate with neurologic function, which can range from isolated spastic paraparesis to profound global developmental delay. **AGS Subtypes by Genotype:**

- *TREX1* (AGS1)
- *RNASEH2A* (AGS2)
- *RNASEH2B* (AGS3)
- *RNASEH2C* (AGS4)
- *SAMHD1* (AGS5)
- *ADAR1* (AGS6)
- *IFIH1* (AGS7)
- *LSM11* (AGS8)
- *RNU7-1* (AGS9)



Potential systemic complications of AGS

<p>Neurologic: Global developmental delay with regression Encephalopathy</p> <p>Ophthalmic: Glaucoma Retinopathy Cortical visual impairment</p> <p>Dermatologic: Chilblains Other inflammatory skin complications</p> <p>Gastrointestinal & urologic: Hepatosplenomegaly Poor GI motility with constipation Failure to thrive Neurogenic bladder with recurrent urinary tract infections Inflammatory bowel disease</p> <p>Hematologic: Anemia Leukopenia Thrombocytopenia Neutropenia</p>	<p>Tone abnormalities, including spastic paraparesis</p> <p>Respiratory: Central apnea Sleep disturbance Pulmonary hypertension Recurrent pneumonia</p> <p>Cardiac: Cardiac hypertrophy Cardiac valve issues</p> <p>Orthopedic: Delayed bone age Hip dysplasia & scoliosis Arthropathy/arthritis</p> <p>Renal: Lupus-like nephropathy Hypertension</p> <p>Endocrinologic: Growth failure Diabetes Hypothyroidism</p>	<p>Seizures Strokes and Moyamoya Myositis</p>
---	---	---

Methodology and cohort description

Data were collected from existing medical records stored in the Myelin Disorders Biorepository Project database. Time to Event curves were created for each systemic event. Genotypes for each event were analyzed separately if there were at least 5 patients of that genotype with the event. RNASEH2A, B, and C were categorized as one genotype. Data were analyzed using Graphpad Prism 9.

Cohort description:

- 186 patients' medical records were reviewed
- The most common AGS-causing mutation in our cohort was RNASEH2B (27.96%). The least common was RNASEH2C (1.61%)
- No patients had LSM11-related AGS at the time of review
- The mean age of AGS presentation was oldest in IFIH1 at 0.81 years and youngest in TREX1 at 0.12 years
- The average time between onset of symptoms and diagnosis was longest for SAMHD1 at 5.38 years and shortest for RNASEH2C at 0.4 years.
- Aside from irritability and lethargy, the most common inflammatory complications were:
 - **Liver Dysfunction** - TREX1, RNASEH2B, ADAR1, IFIH1, and RNU7-1
 - **Anemia** - RNASEH2A and RNASEH2C
 - **Chilblains** - SAMHD1

Results





Figure 1: Cohort characteristics: (a) genotypes; (b) race and ethnicity; (c) time to diagnosis from presenting symptom onset; (d) average age at presentation

Figure 2: Inflammatory systemic events with (a) age of onset and (b) differences by genotype



Discussion

Our study analyzed the time course of fifteen inflammatory events using medical record data from a well-described cohort of people with AGS. Our data highlight that the frequency and time course of systemic inflammatory events vary among AGS genotypes. Additionally, the incidence of most events plateau at different ages for each symptom. **These data show the importance of tailoring clinical screening guidelines to a patient's age and genotype.**

Limitations and future directions

- There may be human error in data abstraction from medical records
- Data for many events assume that no mention of the event meant the event did not occur
- Variability in the information recorded in the medical record limits data quality and quantity, such as at end of life
- The longer time frame for which we have records on a patient, the more likely it is that we captured a systemic event
- Parent recollection and physician interpretation may cause recall bias
- We relied on patients' clinicians to screen for the relevant systemic complications and to document the results of the screening. Screening and charting practices are inconsistent between providers.

The rate of events is likely higher than estimated here. Further studies are needed to determine the actual prevalence and time course of systemic events in AGS.

References and Funding

References

1. Crow YJ, Chase DS, Lowenstein Schmidt J, et al. Characterization of human disease phenotypes associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, ADAR, and IFIH1. *Am J Med Genet A.* 2015;167A(2):296-312. doi:10.1002/ajmg.a.36887
2. Uggenti C, Lepelley A, Depp M, et al. cGAS-mediated induction of type I interferon due to inborn errors of histone pre-mRNA processing. *Nat Genet.* 2020;52(12):1364-1372. doi:10.1038/s41588-020-00737-3

Funding

K23NS114113, U54TR002823
 8 week I-RESTORE research, UC Davis SOM